key: cord-0850526-vdwn4azm authors: Chu, Zi-Qiang; Zhang, Ke-Cheng; Chen, Lin title: Neutrophil extracellular traps in gastrointestinal cancer date: 2021-09-07 journal: World J Gastroenterol DOI: 10.3748/wjg.v27.i33.5474 sha: fd4e17d26d59b5ac0e76725eb4a9e5da83d9f5b7 doc_id: 850526 cord_uid: vdwn4azm Gastrointestinal (GI) cancer is a high-risk malignancy and is characterized by high mortality and morbidity worldwide. Neutrophil extracellular traps (NETs), a weblike structure consisting of chromatin DNA with interspersed cytoplasmic and granule proteins, are extruded by activated neutrophils to entrap and kill bacteria and fungi. However, accumulating evidence shows that NETs are related to the progression and metastasis of cancer. In clinical studies, NETs infiltrate primary GI cancer tissues and are even more abundant in metastatic lesions. The quantity of NETs in peripheral blood is revealed to be associated with ascending clinical tumour stages, indicating the role of NETs as a prognostic markers in GI cancer. Moreover, several inhibitors of NETs or NET-related proteins have been discovered and used to exert anti-tumour effects in vitro or in vivo, suggesting that NETs can be regarded as targets in the treatment of GI cancer. In this review, we will focus on the role of NETs in gastric cancer and colorectal cancer, generalizing their effects on tumour-related thrombosis, invasion and metastasis. Recent reports are also listed to show the latest evidences of how NETs affect GI cancer. Additionally, notwithstanding the scarcity of systematic studies elucidating the underlying mechanisms of the interaction between NETs and cancer cells, we highlight the potential importance of NETs as biomarkers and anti-tumour therapeutic targets. According to cancer statistics, gastric cancer (GC) ranks third globally in terms of mortality, while colorectal cancer (CRC) is the second leading cause of cancer-related death. Both constitute a major cause of cancer-related death worldwide [1, 2] . Despite advances in the techniques applied for cancer treatment, surgical resection accompanied by adjuvant therapy (chemotherapy, radiotherapy and molecular targeted therapies) remains the primary approach [3] . However, the efficacy of aforementioned treatment is related to tumour heterogeneity in patients [4] . Once the tumour progresses and spreads to distant organs (e.g., liver and lung), neither conventional surgery nor targeted therapies can reverse the dismal outcomes [5] . Therefore, it is of high importance in all future studies to understand the mechanisms of deterioration of GI cancer, by measuring not only the tumour itself, but also the surrounding cells that can be modified by the tumour to generate a supportive microenvironment; these cells include macrophages (tumour-associated macrophages), fibroblasts (cancer-associated fibroblasts) and neutrophils (tumour-associated neutrophils) [6, 7] . Neutrophil extracellular traps (NETs) are extruded by activated neutrophils into the extracellular environment and have three-dimensional lattices, which are composed of decondensed chromatin with interspersed proteins such as neutrophil elastase (NE), cathepsin G, myeloperoxidase (MPO), histones and some other antimicrobial peptides [8, 9] . NETs were originally discovered to ensnare and kill extracellular bacteria and fungi and may act as a physical barrier to impede the dissemination of microbes [10] . However, recent studies have revealed that NETs, if dysregulated, can contribute to the development or progression of some inflammatory or immune-related diseases [11, 12] , such as atherosclerosis [ Therefore, more work needs to be done to elucidate the mechanism between NETs and cancer. In this review, we will discuss the role of NETs in GC and CRC according to the latest findings and consider their potential of NETs as biomarkers and therapeutic targets. The formation of NETs, known as NETosis, was first observed by Takei et al [34] via stimulation with phorbol-12-myristate-13-acetate (PMA) and is regarded as a novel form of neutrophil death that is different from apoptosis and necrosis. The antibacterial role of NETs was confirmed in 2004 and is dependent on the web-like structure [10] . The core scaffold of NETs is the nuclear DNA extruded from neutrophils and that forms a three-dimensional meshwork with a number of interspersed specific cytoplasmic and granular proteins [35] . Notwithstanding the lack of mechanistic or interventional studies investigating NET formation in peripheral circulation, initial studies suggest that NETs are released by dying neutrophils. This phenomenon of NET formation can be mainly described by at least two mechanisms. One mechanism requires the lytic suicide of neutrophils, while the other mechanism is independent of this process [36, 37] Recently, an emerging role of NETs in promoting cancer progression has been described. Solid tumours are prone to generating a leukemoid reaction and pre-educate neutrophils to form extracellular DNA traps, and intratumoural NET formation is associated with thrombosis [46] . The accumulation of tumour-induced NETs in the peripheral circulation drives the systemic inflammation and vascular dysfunction in mice with cancer [26] . Leal et al [47] indicates that NETs serve as scaffolds and collaborate with tumour-derived procoagulant exosomes in the establishment of a prothrombotic phenotype in cancer. CXCL8 (interleukin-8, IL8) is a chemokine that can be produced by tumour cells and its role in promoting angiogenesis in cancer has been well discussed [48] . Furthermore, the presence of IL8 activates the extrusion of NETs with potential involvement in cancer progression and promotes cancer cell metastasis partially through AKT and STAT3 signalling pathways [49, 50] . NETs produced by tumour-infiltrating neutrophils mediate the crosstalk between the tumour microenvironment and deterioration by regulating the HMGB1/RAGE/IL8 axis[51]. IL17 is a cytokine described as a protumourigenic factor involved in the initiation and development of cancer [52] . A recent study demonstrated that IL17 can induce NETosis through epithelial cell signalling to favour tumour growth [53] . Rocks et al [54] associated NETs with cancer cells and confirmed that the release of NETs favour tumour cell dissemination and colonization in organs. Since the discovery of NETs, the role of neutrophils and NETs has attracted increasing attentions. Additional studies have reported on numerous stimuli that affect NET formation in vitro and in vivo. PMA, a potent artificial activator of the neutrophil respiratory burst, has been broadly applied to identify the mechanism of NETosis. Cytokines, such as the aforementioned IL8, IL17 and tumour necrosis factor alpha[55], have been investigated with respect to their role in expediting NET formation. Nicotine, a major addictive component of tobacco, is reported to induce NETosis in a dose-dependent manner, implying potential threats to human health [56] . Moreover, sulfasalazine, a drug used to treat inflammatory bowel disease and rheumatoid arthritis, has been found to significantly promote NETosis by accelerating lipid oxidation [ GC is the fifth most common cancer and ranks third in terms of mortality worldwide. Several studies have tried to confirm the characteristics of NETs in GC and clarify the underlying mechanisms in vitro and in vivo (Table 1) . Notwithstanding advances in diagnosis and therapy, recurrence and metastasis are still common as a result of its high molecular and phenotypic heterogeneity [59] , which contributes to a coagulable state that causes the proliferation and invasion of GC cells [60] [61] [62] [63] . In GC patients, NET formation is significantly upregulated and its increased level is consistent with advanced TNM stage. Moreover, a procoagulant role of NETs in GC has been confirmed. When NETosis is inhibited by DNase I, the levels of TAT and D-dimers are downregulated. Furthermore, NETs obtained from GC patients can also stimulate control plasma to generate thrombin and fibrin [64] . A common target of metastatic gastrointestinal cancer is the peritoneal cavity [65] . The invention of heated intraperitoneal chemotherapy[66] and postoperative chemotherapy[67] has indeed reduced the rate of peritoneal recurrence and metastasis. However, limitations still exist with regard to the benefit of these treatments, and severe general toxicity has always been an unavoidable side effect. To elucidate the underlying mechanisms, Kanamaru et al [68, 69] collected the peritoneal lavages from GC patients before and after radical surgery. Then NET formation emerged after short term culture of purified low-density neutrophils (LDNs) separated from the lavages fluids. Moreover, the majority of NET-like structures were discovered on the surface of omental tissue. In a in vivo study, GC cells lines such as MKN45, OCUM-1 and NUGC-4 were found attached to the NETs and remained healthy; this interaction was entirely prevented upon treatment with DNase I, which can degrade NETs. Notwithstanding the advances of therapeutic strategies in GC, surgical resection remains the mainstay treatment. Therefore, the subsequent surgical stress, which suppresses immunity, constitutes one of the key factors that influence the prognosis of GC patients [70, 71] . The percentage of LDNs in the peripheral circulation of GC patients who underwent abdominal surgery was elevated and in vitro studies observed the adhesion of cancer cells to NET structure, suggesting that partial adverse effects of surgical stress may be explained by the formation of NETs [72] . According to a pulmonary metastasis model of GC, accumulation of neutrophils in the adjacent vascular vessels has been found during the colonization of GC cells. Extracts from the root of Salvia miltiorrhiza (Danshen) [73] , a medicinal plant used for cancer therapy, have been observed to prevent neutrophil trafficking to the metastatic sites and obstruct the formation of NETs via inhibitory activities on MPO and NADPH oxidase (NOX) [74] . A recent study has proposed that obstruction of NETosis by Clamidine or DNase I significantly suppresses the progression of GC cells by regulating the expression of apoptosis-associated genes, among which Bcl-2 [75] levels were downregulated and the expression of Bax [76] and NF-κB p65[77] increased significantly [78] . CRC is the third most frequent malignancy and second leading cause of cancer-related mortality worldwide. To date, metastasis and cancer-associated thrombosis are still the main causes of death in CRC patients. To address this issue, much work has been done or is currently in progress; recently, more attention has been drawn to the establishment of tumour microenvironment. Of note, recent accumulating evidence has shown that NETs may play a pivotal role in the progression of CRC (Table 2) . CRC patients are at high risk of venous thrombosis as a result of hypercoagulable state and the levels of NETs in the peripheral blood are positively related to cancer progression. A comparison between 60 newly diagnosed CRC patients and 20 healthy controls revealed that neutrophils in CRC patients can release more NETs, and this tendency parallels increased TAT levels and fibrin formation, which is indicative of a hypercoagulable state [79] . Thus, a vicious cycle can be established between activated platelets and neutrophils. Additionally, in vitro studies show that NETs can convert endothelial cells to a procoagulant phenotype [80] . Another study observed that NETs were concentrated in the centre of CRC tissues and reduced gradually towards adjacent normal tissues, and this characteristic could help surgeons determine a better surgical area through pathological examination of the tumour margins. Furthermore, tissue factor, a stimulus of coagulation and a pro-angiogenic factor, was discovered in NETs from the primary tumour and metastatic lymph nodes[81]. Altogether, the presence of NETs contributes to thrombosis in CRC. By analysing large-scale human data, Rayes et al [82] demonstrated that NETs can not only bind tumour cells but also promote metastasis. In addition, established preclinical models of gastrointestinal cancer revealed that tumours induce neutrophils to extrude NETs into the extracellular environment in the absence of surgical stress. Furthermore, NET formation could promote CRC metastasis after surgical stress [83, 84] . In a cohort study, increased postoperative NET formation was associated with disease-free survival in patients undergoing hepatic surgical resection, and the mouse model of surgical stress has obtained similar results. Further studies demonstrated that the hypoxic environment in solid tumours provides a favourable condition for NETosis and that NETs could in turn promote CRC progression by releasing HMGB1 [85] , a DNA-binding protein that participates in the activation of TLR9 [86] . Additionally, the protumourigenic effects of NETs are abolished by DNase and PAD4 inhibition [83] . Another clinical trial suggested that increased preoperative NETosis is related to an increased hospital stay and complications of CRC patients who undergo colorectal resection, suggesting a promising therapeutic benefit of surgery focused on the relationship between CRC and NETs [84] . In malignant and premalignant colon tissues, CD68+ polyP-expressing cells and NETosis were detected, suggesting a possible interaction between them in the tumour microenvironment. Further investigation indicates that polyP [87] , which is secreted by activated platelets and could induce inflammation and thrombosis in CRC, may promote the formation of NETs [88] . A PAD4-KO mouse model, which is genetically incapable of NETosis, showed that inhibition of NETs halted CRC growth through its negative regulation of mitochondrial biogenesis-associated genes. Further studies show that CRC cells subjected to hypoxia have upregulated expression of HMGB1 [85] , which acts as an inducer of NETosis, and NE released from NETs could assist tumour proliferation as a result of inducing mitochondrial biogenesis by activating the TLR4-p38-PGC1α pathway in CRC [89] . In CRC, IL8 has been reported to participate in growth, angiogenesis and metastasis [90] . High expression of IL8 also implicates adverse survival in patients. A recent study explains a promotional role of IL8 in the formation of NETs. In vitro adhesion system, CRC cells such as HT29 and MC38 cells are more prone to be entrapped into NETs than neutrophil monolayers, giving the chance for disseminated CRC cells to form micrometastases in the liver; this process can be enhanced by overexpression of IL8 [91] . Another study focuses on exosomes secreted by CRC cells. The authors showed that exosomes derived from KRAS mutant cells could transfer mutant KRAS to receptors and upregulate IL8 Levels, eventually activating neutrophils to form NETs and leading to enhanced proliferation and invasion of cancer cells [92] . The aforementioned studies have highlighted an interaction between CRC cells and NETs, suggesting that NET formation is enhanced in tumours and that the increase in NETs can promote the progression and metastasis of CRC. Although several pathways have been described, the detailed mechanisms of how NETs interact with and boost the metastasis of CRC remain elusive. Most recently, a remarkable discovery not only precisely illustrates the underlying mechanism between CRC cells and NETs but also partially explains why CRC cells have a tendency to disseminate into the liver. Yang et al [93] investigated several metastatic lesions in the clinic and discovered the most abundant NET infiltration in liver metastases and the formation of NETs began before the appearance of the metastases. According to a pull-down assay, CCDC25, a potential cell-surface DNA receptor, was identified on the cytoplasmic membrane of cancer cells. Furthermore, amino acids 21-25 at the extracellular N-terminus of CCDC25 were found to be the binding site of NET-DNA. Further immunoprecipitation assays indicated that the intracellular C-terminus of CCDC25 binds integrinlinked kinase and that this interaction can be stimulated by NET-DNA, eventually inducing liver metastases of CRC cells via initiating the β-parvin-RACI-CDC42 cascade. An increasing number of investigations have suggested a protumourigenic role of NETs in providing a microenvironment favouring interactions and promoting cancer proliferation, thrombosis and metastasis in GI cancers. This has led to the question of whether NETs can act as potential biomarkers and therapeutic targets. Zhang et al [94] compared the levels of NETs in different patient populations, suggesting that NETs, as a diagnostic biomarker, have better value than carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 in GC. Additionally, NET formation is associated with tumour stage, poor overall survival and poor recurrence-free survival. Moreover, tumour-infiltrating NETs has been demonstrated to be an independent prognostic biomarker according to the assessment of clinical outcomes of cancer patients [95] [96] [97] . Considering the potential diagnostic significance of NETs, conventional histological staining is ineffective for their detection in tissue. To solve this problem, a protocol has been created to detect NETs in paraffin-embedded tissue [98] . Additionally, machine learning is described as a useful tool to quantitate NETosis [99] . Citrullinated histone H3, a central marker of NETs, is elevated in blood and regarded as a potential diagnostic and prognostic serum marker to predict the risk of venous thromboembolism and mortality in patients with advanced cancer [100] [101] [102] . A CitH3DNA binding assay has also been developed to quantify NET formation [103] . Taking into account the confirmed role of NETs in promoting the progression and metastasis of GI cancer cells, disruption of NETosis can be a possible new therapeutic strategy and the identification of NETosis inhibitors is of high interest. DNase I can degrade the DNA backbone of NETs and abrogate the protumourigenic ability of NETs in several aforementioned animal models. Moreover, DNase I has been safely used in cystic fibrosis and SLE patients [104] , implying that DNase I can act as a promising candidate for the treatment of GI cancer patients. In a mouse model of CRC liver metastasis, an adeno-associated virus gene therapy vector was created to specifically express DNase I in the liver, inducing an inhibition of liver metastasis [105] . However, it is worth noting that everything is a double-edged sword. Inappropriate use of DNase I may lead to a systemic inflammatory response in patients [106] . Owing to the critical role of NE and PAD4 in the process of NETosis, NE inhibitors or PAD4inhibitors are also commonly used to prevent the release of NETs. Nanoparticlemediated delivery of NE inhibitors has been suggested as a feasible approach to decrease NETosis[107]. In addition, NOX inhibitors [108] , MPO inhibitors [109] and RAF inhibitors [110] have been reported to arrest the inception of NETosis. Recently, a group of tetrahydroisoquinolines was found to be a novel class of NET formation inhibitors, but their underlying mechanism remains to be determined [111] . A drug screening of 126 compounds shows that appropriate use of anthracyclines (drugs used for cancer treatment) together with dexrazoxane could be a promising therapeutic candidate for suppressing NETosis without cytotoxicity against healthy neutrophils [112] . NET-associated CEA cell adhesion molecule 1 (CEACAM1) was identified by Rayes et al [113] Knockdown of CEACAM1 on NETs abrogates the adhesion between NETs and colon cancer cells, thus indicating a potential therapeutic therapy or preventing liver metastases. A novel study revealed that PKCα, a lamin kinase that mediates the phosphorylation of lamin B, contributes to the formation of NETs; hence, blocking PKCα provides a new perspective towards treating NET-associated cancer progression [114] . Since the application of 5-fluorouracil (5FU) has been shown to trigger the formation of NETs in the blood of cancer patients, Amph-PVP self-assembled nanoparticles are proposed as an efficient delivery system for 5FU to avoid the generation of NETs, partially improving the anticancer effect and reducing the risk of long-term metastasis [115] . The previously mentioned studies mainly focus on the inhibition of NETosis or the proteins assembled in NETs. Unusually, Cao and King [116] proposed that NETs per se can be utilized as an anti-tumour drug delivery vehicle. By re-engineering neutrophils, supercharged eGFP-TRAIL, an apoptosisinducing chimeric protein, is expressed on NETs to entrap and kill tumour cells. NETs, initially identified as a host defense system designed to trap and kill bacteria, have now been suggested to play an important tumorigenic role in many cancers. Accumulating evidence has shown that NETs are involved in GI cancers, including GC and CRC. As mentioned above, NET infiltration in primary tumour tissues implies a poor outcome in GI cancer patients, indicating that a rapid intraoperative histopathological examination of NETs in the resected tissue margins may help determine the range of surgical resection. Moreover, several cytokines and genetic mutations trigger the formation of NETs and NETs per se can promote the progression of cancer partially by initiating downstream signalling pathways. On the other hand, the fact that NETs can entrap disseminated cancer cells, combined with the situation that an abundance of NET infiltration in the liver is formed before metastases can be detected, increases the likelihood of liver metastasis and explains the high incidence of liver metastasis in patients with GI cancer. Further studies are needed to elucidate the detailed underlying mechanism of the interaction between NETs and GI cancer. Clarifying the roles of NETs in cancer could open a new door in the design and development of therapeutic approaches. Transforming inhibitors of NETs into drugs that can be safely used in GI cancer patients or utilizing NETosis as a drug delivery system may evolve into promising anti-tumour therapies. Cancer statistics Cancer-associated venous thromboembolism: Burden, mechanisms, and management Procoagulant role of neutrophil extracellular traps in patients with gastric cancer Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Advances in the treatment of gastric cancer Low density neutrophils (LDN) in postoperative abdominal cavity assist the peritoneal recurrence through the production of neutrophil extracellular traps (NETs) Neutrophil Extracellular Traps Generated by Low Density Neutrophils Obtained from Peritoneal Lavage Fluid Mediate Tumour Cell Growth and Attachment Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses Clinical review: immunodepression in the surgical patient and increased susceptibility to infection Surgical Stress Increases Circulating Low-Density Neutrophils Which May Promote Tumour Recurrence The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review Polypharmacological Profiles Underlying the Antitumour Property of Salvia miltiorrhiza Root (Danshen) Interfering with NOX-Dependent Neutrophil Extracellular Traps SLPI promotes the gastric cancer growth and metastasis by regulating the expression of P53, Bcl-2 and Caspase-8 Pachymic Acid Sensitizes Gastric Cancer Cells to Radiation Therapy by Upregulating Bax through Hypoxia NF-κB Signaling in Gastric Cancer Destruction of Neutrophil Extracellular Traps Promotes the Apoptosis and Inhibits the Invasion of Gastric Cancer Cells by Regulating the Expression of Bcl-2, Bax and NF-κB Genes associated with venous thromboembolism in colorectal cancer patients Neutrophil extracellular traps induced by activated platelets contribute to procoagulant activity in patients with colorectal cancer Gradient Infiltration of Neutrophil Extracellular Traps in Colon Cancer and Evidence for Their Involvement in Tumour Growth Primary tumours induce neutrophil extracellular traps with targetable metastasis promoting effects Neutrophil Extracellular Traps Promote the Development and Progression of Liver Metastases after Surgical Stress Characterization of systemic neutrophil function in patients undergoing colorectal cancer resection HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer A biadjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer Interferon lambda1/IL-29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation Mast cells coexpressing CD68 and inorganic polyphosphate are linked with colorectal cancer Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumours to Augment Growth The Role of Interleukins in Colorectal Cancer IL-8 mediates a positive loop connecting increased neutrophil extracellular traps (NETs) and colorectal cancer liver metastasis Exosomal KRAS mutation promotes the formation of tumour-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25 Therapeutic Predictive, and Prognostic Value of Neutrophil Extracellular Traps in Patients With Gastric Adenocarcinoma Prognostic Role of Blood NETosis in the Progression of Head and Neck Cancer Tumour-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma Preoperative leukocytosis is associated with increased tumour-infiltrating neutrophil extracellular traps and worse outcomes in esophageal cancer Immunofluorescence Labelling of Human and Murine Neutrophil Extracellular Traps in Paraffin-Embedded Tissue Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients Quantification of Citrullinated Histone H3 Bound DNA for Detection of Neutrophil Extracellular Traps Recombinant human Dnase I (rhDNase) in patients with lupus nephritis AAV-mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune response Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines Inhibition of neutrophil elastase prevents neutrophil extracellular trap formation and rescues mice from endotoxic shock Novel cell death program leads to neutrophil extracellular traps Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation Tetrahydroisoquinolines: New Inhibitors of Neutrophil Extracellular Trap (NET) Formation Anthracyclines Suppress Both NADPH Oxidase-Dependent and -Independent NETosis in Human Neutrophils Neutrophil Extracellular Trap-Associated CEACAM1 as a Putative Therapeutic Target to Prevent Metastatic Progression of Colon Carcinoma Nuclear envelope rupture and NET formation is driven by PKCα-mediated lamin B disassembly Fluorouracil neutrophil extracellular traps formation inhibited by polymer nanoparticle shielding